Original article on AP News
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events — QR-421a is the second ophthalmology program where clinical activity was predicted by translational models, further validating the platform — COVID-19 pandemic expected to impact timelines for the pipeline — ProQR anticipates its cash runway will fund operations into H2 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read February is low vision awareness month and therefore it is the right time to give you this important news. In fact, through our channels we urged supporters to organize Facebook fundraisers in favor of NoisyVision, clarifying that all the funds raised will be donated to research on retinal dystrophies.
Read